Alessandra Viganò
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Alessandra Viganò has a total of 79 co-authors. Here are the top co-authors by number of shared publications:
- Gianvincenzo Zuccotti
Pediatric Department, Buzzi Children’s Hospital, 20154 Milan, Italy
13 shared publications Vania Giacomet
Pediatric Clinic, L. Sacco Hospital, University of Milan, Milan, Italy
9 shared publicationsChiara Cerini
“L. Sacco” Hospital, University of Milan
5 shared publicationsValeria Manfredini
5 shared publications- Giorgio Bedogni
Department of Medical and Surgical Sciences Alma Mater Studiorum‐University of Bologna Bologna Italy
4 shared publications - Vania Giacomet
Department of Pediatrics, L. Sacco Hospital, University of Milan, Italy
4 shared publications
Latest Publications
- 1 September 2014
- Published by Elsevier in Asian Pacific Journal of Tropical Disease
- Vol. 4, S656-S658
A case of laryngeal tuberculosis in a pediatric patient
- 1 September 2014
- Published by Elsevier in Asian Pacific Journal of Tropical Disease
- Vol. 4, S656-S658
A case of laryngeal tuberculosis in a pediatric patient
- 1 October 2012
- Published by Wolters Kluwer Health in The Pediatric Infectious Disease Journal
- Vol. 31 (10) , 1059-1060
Splenomegaly and Variceal Bleeding in a Ten-year-old HIV-infected Girl With Noncirrhotic Portal Hypertension
Noncirrhotic portal hypertension is an uncommon liver disease of unknown origin, increasingly described in HIV-infected adults. Prolonged antiretroviral exposure, in particular to didanosine, and thrombophilic predisposition have been suggested as potential pathogenic factors. Data are limited in children. We describe a 10-year-old HIV-infected girl with noncirrhotic portal hypertension who presented with progressive spleen enlargement and variceal bleeding.
- 1 October 2012
- Published by Wolters Kluwer Health in The Pediatric Infectious Disease Journal
- Vol. 31 (10) , 1059-1060
Splenomegaly and Variceal Bleeding in a Ten-year-old HIV-infected Girl With Noncirrhotic Portal Hypertension
Noncirrhotic portal hypertension is an uncommon liver disease of unknown origin, increasingly described in HIV-infected adults. Prolonged antiretroviral exposure, in particular to didanosine, and thrombophilic predisposition have been suggested as potential pathogenic factors. Data are limited in children. We describe a 10-year-old HIV-infected girl with noncirrhotic portal hypertension who presented with progressive spleen enlargement and variceal bleeding.
- Open Access
- 6 August 2012
- Published by Springer Nature in BMC Infectious Diseases
- Vol. 12 (1) , 179
Efficacy and safety of a dual boosted protease inhibitor-based regimen, atazanavir and fosamprenavir/ritonavir, against HIV: experience in a pediatric population
Although dual-boosted protease inhibitors regimen is not recommended in children with HIV infection, such a strategy could be useful in subjects with a complex resistance profile. This study was aimed at assessing the long term efficacy and safety of a double-boosted protease inhibitor combination, fosamprenavir (fAVP) and atazanavir/ritonavir (ATV/r) in a cohort of HIV-infected children and adolescents who had failed with nucleoside reverse transcriptase inhibitors.
- 6 August 2012
- Published by Springer Nature in BMC Infectious Diseases
- Vol. 12 (1) , 179
Open AccessEfficacy and safety of a dual boosted protease inhibitor-based regimen, atazanavir and fosamprenavir/ritonavir, against HIV: experience in a pediatric population
Although dual-boosted protease inhibitors regimen is not recommended in children with HIV infection, such a strategy could be useful in subjects with a complex resistance profile. This study was aimed at assessing the long term efficacy and safety of a double-boosted protease inhibitor combination, fosamprenavir (fAVP) and atazanavir/ritonavir (ATV/r) in a cohort of HIV-infected children and adolescents who had failed with nucleoside reverse transcriptase inhibitors.
- Open Access
- 1 March 2012
- Published by Brieflands in Hepatitis Monthly
- Vol. 12 (3) , 211-212
Sustained Viral Response and Hematological Adverse Events in Children With Chronic Hepatitis C
Sustained Viral Response and Hematological Adverse Events in Children With Chronic Hepatitis C - Hepatitis Monthly - 2012 - Kowsar
- 1 March 2012
- Published by Brieflands in Hepatitis Monthly
- Vol. 12 (3) , 211-212
Open AccessSustained Viral Response and Hematological Adverse Events in Children With Chronic Hepatitis C
Sustained Viral Response and Hematological Adverse Events in Children With Chronic Hepatitis C - Hepatitis Monthly - 2012 - Kowsar
- Open Access
- 1 March 2012
- Published by Brieflands in Hepatitis Monthly
- Vol. 12 (3) , 211-212
Sustained Viral Response and Hematological Adverse Events in Children With Chronic Hepatitis C
Sustained Viral Response and Hematological Adverse Events in Children With Chronic Hepatitis C - Hepatitis Monthly - 2012 - Kowsar
- 1 March 2012
- Published by Brieflands in Hepatitis Monthly
- Vol. 12 (3) , 211-212
Open AccessSustained Viral Response and Hematological Adverse Events in Children With Chronic Hepatitis C
Sustained Viral Response and Hematological Adverse Events in Children With Chronic Hepatitis C - Hepatitis Monthly - 2012 - Kowsar
- 27 July 2011
- Published by American Society for Microbiology in Clinical and Vaccine Immunology
- Vol. 18 (9) , 1503-1509
Long-Term Immunogenicity after One and Two Doses of a Monovalent MF59-Adjuvanted A/H1N1 Influenza Virus Vaccine Coadministered with the Seasonal 2009-2010 Nonadjuvanted Influenza Virus Vaccine in HIV-Infected Children, Adolescents, and Young Adults in a Randomized Controlled Trial
Few data are available on the safety and long-term immunogenicity of A/H1N1 pandemic influenza vaccines for HIV-infected pediatric patients. We performed a randomized controlled trial to evaluate the safety and long-term immunogenicity of 1 versus 2 doses of the 2009 monovalent pandemic influenza A/H1N1 MF59-adjuvanted vaccine (PV) coadministered with the seasonal 2009-2010 trivalent nonadjuvanted influenza vaccine (SV) to HIV-infected children, adolescents, and young adults. A total of 66 HIV-infected patients aged 9 to 26 years were randomized to receive one (group 1) or two (group 2) doses of PV coadministered with 1 dose of SV. The main outcome was the seroconversion rate for PV at 1 month. Secondary outcomes were the geometric mean titer ratios and the seroprotection rates at 1 month for all vaccines, seroconversion rates at 1 month for SV, and longitudinal changes of antibody titers (ABTs) at 1, 2, 6, and 12 months for all vaccines. Groups 1 and 2 had similar CD4 counts and HIV RNA levels during the study. The seroconversion rate for PV was 100% at 1 month in both groups. ABTs for PV were high during the first 6 months and declined below seroprotection levels thereafter. Longitudinal changes in ABTs were similar in groups 1 and 2 for both PV and SV. The side effects of vaccination were mild and mostly local. In HIV-infected children, adolescents, and young adults, the immune response triggered by a single dose of PV was similar to that obtained with a double dose and was associated with long-term antibody response.
- 27 July 2011
- Published by American Society for Microbiology in Clinical and Vaccine Immunology
- Vol. 18 (9) , 1503-1509
Long-Term Immunogenicity after One and Two Doses of a Monovalent MF59-Adjuvanted A/H1N1 Influenza Virus Vaccine Coadministered with the Seasonal 2009-2010 Nonadjuvanted Influenza Virus Vaccine in HIV-Infected Children, Adolescents, and Young Adults in a Randomized Controlled Trial
Few data are available on the safety and long-term immunogenicity of A/H1N1 pandemic influenza vaccines for HIV-infected pediatric patients. We performed a randomized controlled trial to evaluate the safety and long-term immunogenicity of 1 versus 2 doses of the 2009 monovalent pandemic influenza A/H1N1 MF59-adjuvanted vaccine (PV) coadministered with the seasonal 2009-2010 trivalent nonadjuvanted influenza vaccine (SV) to HIV-infected children, adolescents, and young adults. A total of 66 HIV-infected patients aged 9 to 26 years were randomized to receive one (group 1) or two (group 2) doses of PV coadministered with 1 dose of SV. The main outcome was the seroconversion rate for PV at 1 month. Secondary outcomes were the geometric mean titer ratios and the seroprotection rates at 1 month for all vaccines, seroconversion rates at 1 month for SV, and longitudinal changes of antibody titers (ABTs) at 1, 2, 6, and 12 months for all vaccines. Groups 1 and 2 had similar CD4 counts and HIV RNA levels during the study. The seroconversion rate for PV was 100% at 1 month in both groups. ABTs for PV were high during the first 6 months and declined below seroprotection levels thereafter. Longitudinal changes in ABTs were similar in groups 1 and 2 for both PV and SV. The side effects of vaccination were mild and mostly local. In HIV-infected children, adolescents, and young adults, the immune response triggered by a single dose of PV was similar to that obtained with a double dose and was associated with long-term antibody response.
- 1 June 2011
- Published by Springer Nature in Clinical Drug Investigation
- Vol. 31 (6) , 407-415
Long-Term Renal Safety of Tenofovir Disoproxil Fumarate in Vertically HIV-Infected Children, Adolescents and Young Adults
Background and Objective: Sporadic cases of renal toxicity have been reported in HIV-infected children treated with tenofovir disoproxil fumarate (TDF). We assessed the long-term renal safety of TDF in a cohort of vertically HIV-infected children, adolescents and young adults. Methods: We evaluated 26 HIV-infected children, adolescents and young adults, aged 4.9–17.4 years at baseline, every 6 months for 60 consecutive months. At the baseline visit, they had an undetectable viral load and a good immune reconstitution and were being treated with lamivudine, stavudine and a protease inhibitor (PI). At the same visit, stavudine was replaced with TDF and the PI with efavirenz. Serum creatinine, estimated glomerular filtration rate (GFR), urine protein to creatinine ratio, serum phosphate, ratio of the maximum rate of tubular phosphate reabsorption to the GFR (TmPO4/GFR), urine glucose, and urine α1-microglobulin to creatinine ratio were used as markers of renal function. The outcome-time relationships were studied using generalized estimating equations (GEEs). In addition to time (continuous, ten equally spaced intervals), sex, age at baseline and CD4+ T-cell count were used as covariates. Results: A moderate reduction in GFR was observed only once in an underweight female patient. There was no occurrence of proteinuria, hypophosphataemia or glycosuria. Moreover, TmPO4/GFR was stable and the urine α1-microglobulin to creatinine ratio was always within normal limits. Conclusion: TDF had an excellent renal safety profile in HIV-infected children, adolescents and young adults regularly followed up for 60 months.
- 1 June 2011
- Published by Springer Nature in Clinical Drug Investigation
- Vol. 31 (6) , 407-415
Long-Term Renal Safety of Tenofovir Disoproxil Fumarate in Vertically HIV-Infected Children, Adolescents and Young Adults
Background and Objective: Sporadic cases of renal toxicity have been reported in HIV-infected children treated with tenofovir disoproxil fumarate (TDF). We assessed the long-term renal safety of TDF in a cohort of vertically HIV-infected children, adolescents and young adults. Methods: We evaluated 26 HIV-infected children, adolescents and young adults, aged 4.9–17.4 years at baseline, every 6 months for 60 consecutive months. At the baseline visit, they had an undetectable viral load and a good immune reconstitution and were being treated with lamivudine, stavudine and a protease inhibitor (PI). At the same visit, stavudine was replaced with TDF and the PI with efavirenz. Serum creatinine, estimated glomerular filtration rate (GFR), urine protein to creatinine ratio, serum phosphate, ratio of the maximum rate of tubular phosphate reabsorption to the GFR (TmPO4/GFR), urine glucose, and urine α1-microglobulin to creatinine ratio were used as markers of renal function. The outcome-time relationships were studied using generalized estimating equations (GEEs). In addition to time (continuous, ten equally spaced intervals), sex, age at baseline and CD4+ T-cell count were used as covariates. Results: A moderate reduction in GFR was observed only once in an underweight female patient. There was no occurrence of proteinuria, hypophosphataemia or glycosuria. Moreover, TmPO4/GFR was stable and the urine α1-microglobulin to creatinine ratio was always within normal limits. Conclusion: TDF had an excellent renal safety profile in HIV-infected children, adolescents and young adults regularly followed up for 60 months.
- 1 July 2010
- Published by Bentham Science Publishers Ltd. in Current HIV Research
- Vol. 8 (5) , 411-417
Both HIV-Infection and Long-Term Antiretroviral Therapy are Associated with Increased Common Carotid Intima-Media Thickness in HIV-Infected Adolescents and Young Adults
Objective: To evaluate common carotid artery intima-media thickness (CCIMT) and cardiovascular risk factors in HIV-infected adolescents on combination antiretroviral therapy (cART). Methods: 23 HIV-infected adolescents were matched with 19 healthy subjects by gender, age and body mass index (BMI). CCIMT was measured by Echo-Doppler ultrasound. Bootstrapped multiple linear regression was used to identify potential predictors of CCIMT including HIV status, gender, age, BMI, waist circumference, HDL-cholesterol, LDL- cholesterol, triglycerides, folate, homocysteine and insulin resistance as detected by the homeostasis model assessment, mean blood pressure, and CD36 expression. Results: In the pooled sample, age ranged from 17 to 23 years and BMI between 16.0 and 25.6 kg/m2. Mean (SD) CCIMT was higher in HIV-infected than in healthy subjects [0.5 (0.1) vs 0.4 (0.1) mm, p < 0.001]. Higher values of CCIMT were associated with HIV infection (p < 0.001) and male gender (p < 0.001). CCIMT was also associated with the duration of treatment in subjects with the longest cART exposure, i.e. those exposed to a PI-based and/or NNRTI-based regimen plus a single or double NRTI (p = 0.019). Conclusion: HIV infection and longer duration of cART are associated with higher CCIMT in adolescents and young adults.
- 1 July 2010
- Published by Bentham Science Publishers Ltd. in Current HIV Research
- Vol. 8 (5) , 411-417
Both HIV-Infection and Long-Term Antiretroviral Therapy are Associated with Increased Common Carotid Intima-Media Thickness in HIV-Infected Adolescents and Young Adults
Objective: To evaluate common carotid artery intima-media thickness (CCIMT) and cardiovascular risk factors in HIV-infected adolescents on combination antiretroviral therapy (cART). Methods: 23 HIV-infected adolescents were matched with 19 healthy subjects by gender, age and body mass index (BMI). CCIMT was measured by Echo-Doppler ultrasound. Bootstrapped multiple linear regression was used to identify potential predictors of CCIMT including HIV status, gender, age, BMI, waist circumference, HDL-cholesterol, LDL- cholesterol, triglycerides, folate, homocysteine and insulin resistance as detected by the homeostasis model assessment, mean blood pressure, and CD36 expression. Results: In the pooled sample, age ranged from 17 to 23 years and BMI between 16.0 and 25.6 kg/m2. Mean (SD) CCIMT was higher in HIV-infected than in healthy subjects [0.5 (0.1) vs 0.4 (0.1) mm, p < 0.001]. Higher values of CCIMT were associated with HIV infection (p < 0.001) and male gender (p < 0.001). CCIMT was also associated with the duration of treatment in subjects with the longest cART exposure, i.e. those exposed to a PI-based and/or NNRTI-based regimen plus a single or double NRTI (p = 0.019). Conclusion: HIV infection and longer duration of cART are associated with higher CCIMT in adolescents and young adults.
- 17 January 2010
- Published by Taylor & Francis in Expert Opinion on Drug Safety
- Vol. 9 (3) , 431-445
Metabolic complications associated with antiretroviral therapy in HIV-infected and HIV-exposed uninfected paediatric patients
Importance of the field: HIV-infection has become a chronic disease in paediatric patients with the potential for long-term survival and exposure to antiretroviral (ARV) therapies for 2 decades longer than HIV-infected adults. On the other hand, the administration of ARV to HIV-infected pregnant women has greatly increased both treatment of HIV infection and prevention of perinatal HIV transmission. Therefore, researches aiming to evaluate the safety of ARV therapies in HIV-infected children as well as in HIV-uninfected infants born to HIV-infected mothers are emerging as a new challenge and urgent priority. Areas covered in this review: The purpose of this review is to describe some of the more concerning metabolic complications associated with ARV in paediatric population: hyperlactataemia (HLA) syndromes, body shape abnormalities, disorders of glucose homeostasis and dyslipidaemia in HIV-infected children and adolescents. Frequency, risk factors, clinical findings, prevention and intervention strategies of the previously described abnormalities are discussed in depth. What the reader will gain: This review covers our current understanding of HLA syndromes in ARV-exposed uninfected infants born to HIV-infected mothers. Take home message: Prevention of these metabolic complications should assume prominence and future researches should address several of the existing treatment gaps.
- 17 January 2010
- Published by Taylor & Francis in Expert Opinion on Drug Safety
- Vol. 9 (3) , 431-445
Metabolic complications associated with antiretroviral therapy in HIV-infected and HIV-exposed uninfected paediatric patients
Importance of the field: HIV-infection has become a chronic disease in paediatric patients with the potential for long-term survival and exposure to antiretroviral (ARV) therapies for 2 decades longer than HIV-infected adults. On the other hand, the administration of ARV to HIV-infected pregnant women has greatly increased both treatment of HIV infection and prevention of perinatal HIV transmission. Therefore, researches aiming to evaluate the safety of ARV therapies in HIV-infected children as well as in HIV-uninfected infants born to HIV-infected mothers are emerging as a new challenge and urgent priority. Areas covered in this review: The purpose of this review is to describe some of the more concerning metabolic complications associated with ARV in paediatric population: hyperlactataemia (HLA) syndromes, body shape abnormalities, disorders of glucose homeostasis and dyslipidaemia in HIV-infected children and adolescents. Frequency, risk factors, clinical findings, prevention and intervention strategies of the previously described abnormalities are discussed in depth. What the reader will gain: This review covers our current understanding of HLA syndromes in ARV-exposed uninfected infants born to HIV-infected mothers. Take home message: Prevention of these metabolic complications should assume prominence and future researches should address several of the existing treatment gaps.